Navigation Links
PEAK Surgical Introduces PEAK PlasmaBlade(R) 3.0S
Date:7/8/2010

PALO ALTO, Calif., July 8 /PRNewswire/ -- PEAK Surgical, Inc. today announced the launch of the PEAK PlasmaBlade® 3.0S dissection device following 510(k) clearance from the U.S. Food and Drug Administration (FDA). This revolutionary product features a 3.0mm wide blade for even greater cutting precision, integrated suction for enhanced visibility, and a telescoping shaft that extends from 5.5 cm to 15 cm for improved surgical access. The PlasmaBlade 3.0S is cleared for use in general, plastic and reconstructive, ENT, gynecologic, orthopedic, arthroscopic, spinal and neurological surgical procedures in the United States.

"I have found the PlasmaBlade 3.0S to be an excellent precision dissection instrument for my spine surgery procedures," said John Peloza, M.D., director of the Center for Spine Care in Dallas, Texas. "The PlasmaBlade 3.0S not only precisely cuts and cauterizes pathological tissue but the reduced thermal damage to surrounding healthy tissue has translated into clinical benefits for my patients."

"The access and visibility with the PlasmaBlade 3.0S is excellent," said Helson Pacheco-Serrant, M.D., director of Neurosurgical Specialists of El Paso in El Paso, Texas. "The speed with which I can perform precise dissections near sensitive structures without worrying about thermal spread is a real advantage to both me and my patients. To date, my patients have experienced excellent post-operative recoveries, which I believe is due to the reduced thermal injury profile of this device."

PRECISE Study Results

PEAK Surgical has initiated a series of clinical studies, called the PRECISE Studies (Pulsed Plasma Radiofrequency Energy to ReduCe Thermal Injury and Improve Surgical HEaling), to examine the use of the PlasmaBlade in orthopedic, plastic and reconstructive, ENT and oncologic surgery. Initial study results have been presented at various medical congresses, including American College of Surgeons (ACS) and American Society of Breast Surgeons (ASBS) and additional results are expected later this year. These study results have demonstrated that the PlasmaBlade was associated with significant improvements in the following endpoints as compared with the standard of care:

  • 75 percent reduction in thermal injury depth (p=0.001)
  • 31 percent reduction in inflammation (p = 0.06)
  • 49 percent reduction in post-operative narcotic consumption (p=0.02)
  • 65 and 42 percent stronger healed incision strength at 3 and 6 weeks, respectively (p < 0.001)

"The clinical and economic benefits of the PlasmaBlade are making a positive impact on the healthcare community," said John Tighe, president and chief executive officer of PEAK Surgical. "We continue to see significant adoption of the PlasmaBlade by surgeons and hospitals as more than 25,000 surgical procedures have been performed with the PlasmaBlade to date since its launch in July 2008."

About PEAK Surgical, Inc.

PEAK Surgical, Inc. is a medical device company that has developed the PEAK PlasmaBlade®, a new tissue dissection device based on a proprietary technology that represents an important advance in radiofrequency surgical technologies. The PlasmaBlades are a family of disposable cutting devices that offer the exacting control of a scalpel and the bleeding control of traditional electrosurgery without extensive collateral damage. These surgical devices come together with the PULSAR® Generator, which supplies pulsed plasma radiofrequency energy to the PlasmaBlades, to form the PEAK® Surgery System. The PEAK Surgery System is cleared for use in general, plastic and reconstructive, ENT, gynecologic, orthopedic, arthroscopic, spinal and neurological surgical procedures in the United States, and for use in general surgery in the EU. In the United States, the PEAK Surgery System was launched in July 2008 and has been used by U.S. surgeons on more than 25,000 patients. For more information, please visit www.peaksurgical.com.


'/>"/>
SOURCE PEAK Surgical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Surgical Equipment Market to 2016 - Emerging Economies to Provide Future Growth Opportunities
2. Reportlinker Adds Opportunities in Non-Surgical Bio-Implants: Marketed injectable biomaterials, applications, and leading players
3. PolyTouch Medical Ltd. Receives FDA Clearance to Commercialize PatchAssist(TM) - an Innovative Surgical Instrument Intended to Facilitate the Delivery of Soft Tissue Prosthetics During the Laparoscopic Repair of Soft Tissue Defects
4. Novus Scientific Announces the Sales Launch for TIGR™ Matrix Surgical Mesh - Worlds 1st Long-Term Resorbable Synthetic Mesh
5. Brainlab Collaborates With Toshiba Medical Systems on Integrated Surgical Suite
6. Simulated Surgical Systems, LLC Partners to Bring Simulation Advances to Surgical Training
7. KENSEY NASH Receives FDA 510(k) Clearance for ECM Product, Meso BioMatrix Surgical Mesh
8. Ethicon Endo-Surgery Introduces Two New Staplers for Open Surgical Procedures at ASCRS
9. Ethicon Endo-Surgery Introduces HARMONIC FOCUS(R) Long Curved Shears for Deep Surgical Access
10. MitraClip Safely Relieves Symptoms in Patients With No Surgical Options
11. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... Jan. 18, 2017   Spotlight Innovation Inc. ... Therapeutics plans, in the second quarter of 2017, ... roll-on intended to provide relief from chronic pain, ... analgesics. It was developed under a licensing agreement ... products derived from snake venom. Additionally, Caretta Therapeutics ...
(Date:1/18/2017)... 2017  Kratom leaves, from a South East ... used to prepare tea-like beverages and commercially manufactured ... annually to increase alertness, enhance well-being and occupational ... aches and pains. PinneyAssociates, review of the scientific ... FDA and DEA in determining the most appropriate ...
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
Breaking Medicine Technology:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... asset protection and financial planning services to families and business owners in the ... aimed at supporting children with developmental disabilities. , The Lakemary Center is a ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... ... communications company, launched a new website for its Center for Biosimilars, announced Michael ... include the latest developments in the field of biosimilars through thought leader interaction ...
(Date:1/18/2017)... ... January 18, 2017 , ... Floundering on New Year’s resolutions? Need an excuse ... for a reset. The U.S. Apple Association agrees and recommends starting each day ... that contribute to heart disease. , The U.S. Apple Association – which represents apple ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... difference. Eden Activewear is a stand-out company for several differences from other mainstream ... only manufacture on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html . ...
(Date:1/17/2017)... ... January 17, 2017 , ... SunView Software’s Service Smart Technology has ... the Year. , Each year, Pink Elephant recognizes a new product or ... address a specific business problem or opportunity. The award highlights original innovations that were ...
Breaking Medicine News(10 mins):